Paolo Tarantino: Randomized phase 2 trial of neoadjuvant ARX788 + Pyrotinib vs TCHP for HER2+ BC
Paolo Tarantino, Clinical Research Fellow at Dana-Farber Cancer Institute, shared on X about a recent paper shared by Nan Niu et al. published in Nature:
“Randomized phase 2 trial of neoadjuvant ARX788 (anti-microtubule HER2 ADC) + pyrotinib vs TCHP for HER2+ BC (n=136). pCR rate 70% vs 51% (p=0.02). Poor tolerability of the ADC combo, with 99% diarrhea, frequent liver disfunction, 43% ILD, 75% ocular tox. ”
Title: Neoadjuvant ARX788 plus pyrotinib versus trastuzumab, pertuzumab, docetaxel and carboplatin for HER2-positive breast cancer: a randomised phase 2b trial
Authors: Nan Niu, Jinqi Xue, Guanglei Chen, Fang Qiu, Qianshi Xu, Xinyu Zheng, Chao Liu, Yafei Zhao, Xi Gu, Yi Zhao, Hong Xu, Hao Zhang, Guijin He, Ke Li, Pengfei Li, Xiaoying Chen, Yong Li, Shuo Wang, Demiao Zhu, Tong Liu, Fei Xing, Yongqing Xu, Ye Han, Meiyue Tang, Mingxin Liu, Gege Jiao, Xiaofan Jiang, Tony Yuen, Zheng Pang and Caigang Liu
More posts featuring Paolo Tarantino.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023